



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Aminohexylgeldanamycin

<b>Cat. No.:</b>	HY-133571
<b>CAS No.:</b>	485395-71-9
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>52</sub> N <sub>4</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	644.8
<b>Target:</b>	HSP; ADC Cytotoxin
<b>Pathway:</b>	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 110 mg/mL (170.60 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	1.5509 mL	7.7543 mL	15.5087 mL
		5 mM	0.3102 mL	1.5509 mL	3.1017 mL
	10 mM	0.1551 mL	0.7754 mL	1.5509 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 4.25 mg/mL (6.59 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 4.25 mg/mL (6.59 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	HSP90
<b>In Vitro</b>	HPMA copolymer-aminohexylgeldanamycin conjugates target cell surface expressed GRP78 in prostate cancer <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

---

[1]. Greish K, et al. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release. 2011;151(3):263-270.

[2]. Larson N, et al. HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer. Pharm Res. 2010;27(12):2683-2693.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA